Bhupesh Dihenia, MD
Neurology · Lubbock, TXNPI 1205835022
Payments from drug & device makers
Across 474 payments — averaging $14,583 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4.8M
- F. Hoffmann-la Roche AG$969K
- Genentech, Inc.$518K
- AbbVie$465K
- Bristol Myers Squibb$65K
- EMD Serono, Inc.$39K
- plus $38K from 31 others
Across 29 payments — averaging $2341.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$68K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $4,818,716 |
| F. Hoffmann-la Roche AG | 118 | $968,920 |
| Genentech, Inc. | 24 | $517,553 |
| AbbVie | 52 | $465,420 |
| Bristol Myers Squibb | 5 | $64,751 |
| EMD Serono, Inc. | 9 | $39,180 |
| Biogen | 4 | $25,996 |
| Alkermes, Inc. | 6 | $8,390 |
| Teva Pharmaceuticals USA, Inc. | 141 | $1,080 |
| Ares Trading SA | 8 | $680 |
| Harmony Biosciences LLC | 3 | $216 |
| Biohaven Pharmaceuticals, Inc. | 28 | $178 |
| Pfizer | 9 | $148 |
| Sanofi | 2 | $148 |
| Eisai Inc. | 4 | $99 |
| ANI Pharmaceuticals, Inc. | 6 | $88 |
| Lundbeck LLC | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| AstraZeneca | 2 | $54 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Neurocrine Biosciences, Inc. | 3 | $44 |
| Acorda Therapeutics, Inc | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Medtronic | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Argenx US, Inc. | 1 | $26 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Philips North America LLC | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| GE HealthCare | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Insightec,inc | 1 | $6 |
How this compares
$6,912,186 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Lubbock
- Mirla AvilaLubbock$1.3M
- Ahmad SabouniLubbock$737K
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.